A novel functional polymorphism in the uridine diphosphate- glucuronosyltransferase 2B7 promoter with significant impact on promoter activity

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 3, 2004, Pages 223-233

  Duguay, Yannick ^b   Báár, Cecilie ^b   Skorpen, Frank ^b   Guillemette, Chantal ^a  

^a Chaires de recherche du Canada   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE;

ADULT; AGED; ARTICLE; CANCER PAIN; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE ACTIVITY; GENE CONSTRUCT; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LIQUID CHROMATOGRAPHY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; SINGLE NUCLEOTIDE POLYMORPHISM; START CODON;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BASE SEQUENCE; CACO-2 CELLS; CELL LINE, TUMOR; FEMALE; GENE FREQUENCY; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS);

EID: 1542286160     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2003.10.006     Document Type: Article

References (35)

1. Andersen G., Christrup L., Sjogren P. Relationships among morphine metabolism, pain and side effects during long-term treatment an update. J Pain Symptom Manage. 25:2003;74-91.
2. McQuay H.J., Carroll D., Faura C.C., Gavaghan D.J., Hand C.W., Moore R.A. Oral morphine in cancer pain influences on morphine and metabolite concentration. Clin Pharmacol Ther. 48:1990;236-244.
3. Klepstad P., Kaasa S., Borchgrevink P.C. Start of oral morphine to cancer patients effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol. 55:2000;713-719.
4. Faura C.C., Collins S.L., Moore R.A., McQuay H.J. Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain. 74:1998;43-53.
5. Brunk S.F., Delle M. Morphine metabolism in man. Clin Pharmacol Ther. 16:1974;51-57.
6. Yeh S.Y., Gorodetzky C.W., Krebs H.A. Isolation and identification of morphine 3- and 6-glucuronides, morphine 3,6-diglucuronide, morphine 3-ethereal sulfate, normorphine, and normorphine 6-glucuronide as morphine metabolites in humans. J Pharm Sci. 66:1977;1288-1293.
7. Osborne R., Joel S., Grebenik K., Trew D., Slevin M. The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther. 54:1993;158-167.
8. Pasternak G.W., Bodnar R.J., Clark J.A., Inturrisi C.E. Morphine-6-glucuronide, a potent mu agonist. Life Sci. 41:1987;2845-2849.
9. Pasternak G.W. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci. 22:2001;67-70.
10. Gong Q.L., Hedner T., Hedner J., Bjorkman R., Nordberg G. Antinociceptive and ventilatory effects of the morphine metabolites morphine-6-glucuronide and morphine-3-glucuronide. Eur J Pharmacol. 193:1991;47-56.
11. Osborne R., Thompson P., Joel S., Trew D., Patel N., Slevin M. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol. 34:1992;130-138.
12. Bodenham A., Quinn K., Park G.R. Extrahepatic morphine metabolism in man during the anhepatic phase of orthotopic liver transplantation. Br J Anaesth. 63:1989;380-384.
13. Yue Q.Y., Odar-Cederlof I., Svensson J.O., Sawe J. Glucuronidation of morphine in human kidney microsomes. Pharmacol Toxicol. 63:1988;337-341.
14. Pacifici G.M., Bencini C., Rane A. Presystemic glucuronidation of morphine in humans and rhesus monkeys subcellular distribution of the UDP-glucuronyltransferase in the liver and intestine. Xenobiotica. 16:1986;123-128.
15. Wahlstrom A., Winblad B., Bixo M., Rane A. Human brain metabolism of morphine and naloxone. Pain. 35:1988;121-127.
16. King C.D., Rios G.R., Assouline J.A., Tephly T.R. Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate. Arch Biochem Biophys. 365:1999;156-162.
17. King C.D., Rios G.R., Green M.D., Tephly T.R. UDP- glucuronosyltransferases. Curr Drug Metab. 1:2000;143-161.
18. Coffman B.L., Rios G.R., King C.D., Tephly T.R. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 25:1997;1-4.
19. Radominska-Pandya A., Little J.M., Czernik P.J. Human UDP-glucuronosyltransferase 2B7. Curr Drug Metab. 2:2001;283-298.
20. Toide K., Takahashi Y., Yamazaki H., Terauchi Y., Fujii T., Parkinson A., et al. Hepatocyte nuclear factor-1alpha is a causal factor responsible for interindividual differences in the expression of UDP-glucuronosyltransferase 2B7 mRNA in human livers. Drug Metab Dispos. 30:2002;613-615.
21. Strassburg C.P., Barut A., Obermayer-Straub P., Li Q., Nguyen N., Tukey R.H., et al. Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase UGT2B7. J Hepatol. 34:2001;865-872.
22. Innocenti F., Iyer L., Ramirez J., Green M.D., Ratain M.J. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos. 29:2001;686-692.
23. Strassburg C.P., Kneip S., Topp J., Obermayer-Straub P., Barut A., Tukey R.H., et al. Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem. 275:2000;36164-36171.
24. Holthe M., Klepstad P., Zahlsen K., Borchgrevink P.C., Hagen L., Dale O., et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol. 58:2002;353-356.
25. Holthe M., Rakvag T.N., Klepstad P., Idle J.R., Kaasa S., Krokan H.E., et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J. 3:2003;17-26.
26. Guillemette C., Ritter J.K., Auyeung D.J., Kessler F.K., Housman D.E. Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics. 10:2000;629-644.
27. Wittwer C.T., Ririe K.M., Andrew R.V., David D.A., Gundry R.A., Balis U.J. The LightCycler a microvolume multisample fluorimeter with rapid temperature control. Biotechniques. 22:1997;176-181.
28. Sawyer M.B., Innocenti F., Das S., Cheng C., Ramirez J., Pantle-Fisher F.H., et al. A pharmacogenetic study of uridine diphosphate- glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther. 73:2003;566-574.
29. Ishii Y., Hansen A.J., Mackenzie P.I. Octamer transcription factor-1 enhances hepatic nuclear factor-1alpha-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter. Mol Pharmacol. 57:2000;940-947.
30. Jin C., Miners J.O., Lillywhite K.J., Mackenzie P.I. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther. 264:1993;475-479.
31. Coffman B.L., King C.D., Rios G.R., Tephly T.R. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos. 26:1998;73-77.
32. Hirota T., Ieiri I., Takane H., Sano H., Kawamoto K., Aono H., et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos. 31:2003;677-680.
33. Barbier O., Turgeon D., Girard C., Green M.D., Tephly T.R., Hum D.W., et al. 3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos. 28:2000;497-502.
34. Fletcher C.V., Balfour H.H. Jr. Variability in zidovudine serum concentrations. Pharmacotherapy. 16:1996;1154-1158.
35. Marchbanks K., Dudley M.N., Posner M.R., Darnowski J. Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer. Pharmacotherapy. 15:1995;451-457.